Kunal Kapoor launches MetaGO, a doctor-led metabolic health platform

Actor and entrepreneur Kunal Kapoor has launched MetaGO, a doctor-led metabolic health platform, betting that India’s rising burden of obesity and related metabolic diseases requires continuous medical care rather than short-term weight-loss interventions.

Built by the founders of healthcare crowdfunding platform Ketto, the new venture aims to combine specialist consultations, diagnostics, clinically appropriate GLP-1 therapies, nutrition guidance, and long-term clinical monitoring as demand for evidence-based obesity treatment grows.

The launch comes at a time when obesity treatment is undergoing a major transformation worldwide. New GLP-1 medicines, which mimic a naturally occurring hormone that helps regulate appetite and blood sugar, have significantly expanded treatment options.

At the same time, healthcare experts increasingly stress that these medicines work best when combined with medical supervision, lifestyle changes and long-term follow-up rather than being used as standalone solutions.

MetaGO is co-founded by Kapoor, Varun Sheth, and Zaheer Adenwala, who spent more than a decade building Ketto.

According to the co-founders, their experience of helping families raise money for serious medical treatment highlighted a recurring pattern. Many patients facing diabetes, heart disease or obesity-related complications had underlying metabolic problems that had gone untreated for years.

“Fourteen years of building Ketto teaches you to see patterns. We met thousands of families at some of the hardest moments of their lives, often after years of diabetes, obesity, or other metabolic conditions had progressed. Over time, it became clear that many of those conditions had begun developing years before anyone needed medical treatment,” Kapoor said, explaining the motivation behind the healthcare venture.

MetaGO offers an integrated care model combining doctor consultations, metabolic assessments covering more than 35 biomarkers, personalised treatment plans, nutrition guidance, fitness coaching and ongoing monitoring. Where clinically appropriate, treatment may include GLP-1 therapies, but the company notes that tthese form only one part of a broader care plan.

“GLP-1 therapies have genuinely changed what’s possible for many people living with obesity, but medication is only one part of the journey. Lasting outcomes come from combining it with medical supervision, nutrition, behaviour change and ongoing support. Nobody should be left alone with a strong drug and a printout,” Kapoor remarked.

The launch highlights broader changes across the obesity care industry. Pharmaceutical companies including Novo Nordisk and Eli Lilly continue to expand their portfolios of GLP-1 medicines while development of newer oral treatments and next-generation therapies are progressing.

At the same time, regulators are paying closer attention to how obesity medicines are promoted. In India, authorities have increased scrutiny of awareness campaigns to ensure prescription medicines are not indirectly advertised to consumers.